Showing 1 – 20 of 1613
Relevance | Newest | Oldest |
  • Effect of Crohn Disease Biologics

    Abstract Full Text
    JAMA. 2017; 317(20):2055-2055. doi: 10.1001/jama.2017.5897
  • JAMA September 20, 2016

    Figure 1: Flow Diagram of Progress Through Phases of the Randomized Trial Comparing a Non–Tumor-Necrosis Factor (TNF)-Targeted Biologic or a Second Anti-TNF Agent Among Patients With Rheumatoid Arthritis and an Insufficient Response to a First Anti-TNF Agent

    The number of patients screened for eligibility, number excluded, and reasons for exclusion are not available. Patients who during follow-up received any biologic agent different from the treatment initially assigned for any reason continued to be followed up and were considered nonresponders. TNF indicates tumor necrosis factor.aOne patient at 3 months and 1 patient at 12 months who discontinued the study discontinued the intervention (new biologic).bTwo patients who discontinued the study discontinued the intervention (new biologic).
  • Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2016; 316(11):1172-1180. doi: 10.1001/jama.2016.13512

    This pragmatic randomized trial compares the effects of a second anti–tumor necrosis factor (TNF) drug vs non–TNF-targeted biologic therapy among patients with rheumatoid arthritis for whom a first anti-TNF drug had failed.

  • JAMA September 20, 2016

    Figure 2: Evolution of Disease Activity Score in 28 Joints-Erythrocyte Sedimentation Rate (DAS28-ESR) and Health Assessment Questionnaire Score in Non–Tumor-Necrosis Factor (TNF) and Second Anti-TNF Groups

    The analytic sample sizes shown at baseline in Figure 2 differ from the total number randomized because of missing data. They also differ for DAS28-ESR from the numbers included in the primary analysis (European League Against Rheumatism response) because in the primary analysis, some of the patients with missing data were considered nonresponders because they received during the follow-up a biologic agent different from the treatment initially assigned, as specified in the statistical analysis section. Constrained longitudinal data analyses were used for between-group comparisons for DAS28-ESR and HAQ. For DAS-28-ESR, the 12-week P value was .008; 24- week, P = .004; and 52-week, P = .01; for HAQ, the 12-week P value was.09; 24-week, P = .44; and 52-week, P = .75. Data markers represent the mean and error bars 95% CIs. See the Methods section for a definition of disease activity score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and range and the Health Assessment Questionnaire (HAQ) definition and score range.
  • Pragmatic Trials: Practical Answers to “Real World” Questions

    Abstract Full Text
    JAMA. 2016; 316(11):1205-1206. doi: 10.1001/jama.2016.11409

    This Guide to Statistics article compares pragmatic randomized controlled trials, which focus on important challenges that patients, physicians, and policy makers face in day-to-day life with explanatory trials that seek to test a hypothesis.

  • JAMA April 28, 2015

    Figure 3: Definition of 4 Haplotype Groups by 16 Haplotypes Defined by Amino Acid Positions 11, 71, and 74 of HLA-DRB1

    The size of the filled circle representing a haplotype is proportional to its frequency in the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort; the smallest point represents frequencies below 1%. The allocation of haplotypes to groups was performed to group rare haplotypes with frequent ones having similar odds ratios. If the PAA haplotype is set as the reference, then haplotypes associated with a decreased risk to develop rheumatoid arthritis are represented below the dashed line, whereas haplotypes associated with an increased risk are above it. Of the 1846 patients from the BRAGGSS cohort presented in Table 1, 1819 had nonmissing genotypes at the 3 positions used to construct the haplotypes. Group 1 comprises 894 heterozygote patients (1 copy of a group 1 haplotype; eg, VKA or VRA) and 314 homozygote patients (2 copies of VKA or 2 copies of VRA, 1 copy of VKA and VRA). Group 2 comprises 594 heterozygote patients and 46 homozygote patients. Group 3 comprises 715 heterozygote patients and 80 homozygote patients. Group 4 comprises 480 heterozygote patients and 37 homozygote patients. The haplotype frequency presented was calculated as: (No. of heterozygote carriers + 2 × No. of homozygote carriers)/(2 × 1819). The nomenclature for haplotype names is presented in Table 4.
  • JAMA April 28, 2015

    Figure 4: Correlation Between Odds Ratios (ORs) for Susceptibility to Rheumatoid Arthritis (RA) and ORs for Treatment Response in BRAGGSS Cohort

    Treatment response correlates with susceptibility in this Figure. Horizontal and vertical error bars indicate 95% CIs. The orange line was fitted by linear regression. Haplotype groups are defined in Figure 3. The OR for a haplotype group for the association with RA susceptibility has been calculated as the weighted average of the OR of the individual haplotypes belonging to the group; haplotype frequency was used as the weight. The OR for the association with treatment response has been calculated using a multivariable ordinal logistic regression of European League Against Rheumatism response on the haplotype groups. Every patient in the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort carries either 0, 1, or 2 copies of a haplotype classified as a group 1, 2, 3, or 4 haplotype. The multivariable ordinal logistic regression includes all 4 haplotype groups in the same model and the following markers of treatment response as covariates: sex, concurrent treatment with disease-modifying antirheumatic drugs, Disease Activity Score based on 28 joint counts, and Health Assessment Questionnaire disability index score at treatment initiation (baseline). The Disease Activity Score ranges from 0 to 10; a higher score indicates a higher level of disease activity. Health Assessment Questionnaire measures functional disability and ranges from 0 to 3; a higher score indicates a higher level of disability.
  • Total Expenditures per Patient in Hospital-Owned and Physician-Owned Physician Organizations in California

    Abstract Full Text
    free access
    JAMA. 2014; 312(16):1663-1669. doi: 10.1001/jama.2014.14072

    Robinson and Miller determine whether total expenditures per patient were higher in medical groups owned by local hospitals or multihospital systems compared with groups owned by participating physicians in California between 2009 and 2012.

  • Federal Human Research Oversight of Clinical Trials in the United States

    Abstract Full Text
    free access
    JAMA. 2014; 311(9):960-961. doi: 10.1001/jama.2013.284306
  • Selections From News@JAMA and JAMA Forum

    Abstract Full Text
    JAMA. 2013; 309(19):1983-1983. doi: 10.1001/jama.2013.5120
  • Ushering in a New Era of Open Science Through Data Sharing: The Wall Must Come Down

    Abstract Full Text
    free access
    JAMA. 2013; 309(13):1355-1356. doi: 10.1001/jama.2013.1299
  • Letting the Sunshine In

    Abstract Full Text
    JAMA. 2013; 309(10):973-973. doi: 10.1001/jama.2013.1716
  • How to Use an Article Reporting a Multiple Treatment Comparison Meta-analysis

    Abstract Full Text
    JAMA. 2012; 308(12):1246-1253. doi: 10.1001/2012.jama.11228
    Interpreting the results of a multiple treatment comparison (MTC) meta-analysis can be a challenge. Mills and coauthors provide a 3-step approach in this Users’ Guide to help demystify the MTC for clinicians.
  • Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases

    Abstract Full Text
    free access
    JAMA. 2012; 308(1):43-49. doi: 10.1001/jama.2012.7304
    Zhang and colleagues used administrative claims from US Medicare beneficiaries diagnosed with selected immune-mediated diseases to evaluate the association between receipt of zoster vaccine and herpes zoster risk within the first 42 days and up to 3.5 years following vaccination.
  • Still in the Shadows

    Abstract Full Text
    JAMA. 2011; 306(18):1970-1970. doi: 10.1001/jama.2011.1600
  • Registries for Robust Evidence

    Abstract Full Text
    JAMA. 2009; 302(7):790-791. doi: 10.1001/jama.2009.1092
  • Funding Transparency

    Abstract Full Text
    JAMA. 2009; 302(6):619-619. doi: 10.1001/jama.2009.1122
  • FDA Performance Goals for Approving Drugs and Biologics

    Abstract Full Text
    JAMA. 2009; 302(2):189-191. doi: 10.1001/jama.2009.974
  • Clinical Trials Registry Expands

    Abstract Full Text
    JAMA. 2009; 302(1):22-22. doi: 10.1001/jama.2009.891